Autodesk Inc vs Medpace Holdings Inc — how do they compare? Autodesk Inc trades at $249 (market cap $53.12B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Autodesk Inc is far larger — about 3.1× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | MEDP | |
|---|---|---|
Market Cap | $53.12B | $16.90B |
Sector | Technology | Technology |
52-Week High | $326.79 | $620.59 |
52-Week Low | $187.72 | $393.42 |
Enterprise Value | $52.92B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.55, down 2.55% today, but maintains a strong fundamental profile with robust earnings beats, including Q1 2026 EPS of $2.99 versus $2.84 expected. The stock exhibits a bullish technical trend with moving averages supporting upside, though RSI levels indicate potential overbought conditions. Revenue growth is steady, projected to reach $7.5B in 2026, with a high net income margin of 19.49% in 2025.
The outlook remains positive given analyst consensus favoring Buy ratings (74.51%) and a $302.23 price target, implying significant upside. Key risks include competitive pressures in design software and reliance on enterprise spending cycles. Continued execution on AI investments and margin expansion are critical for sustaining valuation multiples.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →